Patients with preserved thymic health before radiotherapy seemed to have greater risk
THURSDAY, Aug. 27, 2026 (HealthDay News) — For patients with non-small cell lung cancer (NSCLC), thymic radiation exposure is independently associated with increased risks for distant metastasis, according to a study published online Aug. 25 in the Annals of Oncology.
Vasco Prudente, from Harvard Medical School in Boston, and colleagues conducted a multicohort analysis of 1,107 patients with NSCLC, including the phase 3 RTOG-0617 trial (460 patients) and two real-world cohorts of patients treated with chemoradiotherapy alone (HARVARD-CRT; 422 patients) or in combination with consolidation immunotherapy (HARVARD-DURVA; 225 patients). Thymic function was quantified using a deep learning system. Thymic radiation exposure was measured using mean thymic dose (MTD).
The researchers found that after confounding adjustments, incidental thymic irradiation was associated with an increased risk for distant metastasis. A 1-Gy increase in MTD was associated with a 1.57 to 4.21 percent increased risk for distant metastasis (adjusted hazard ratios, 1.29, 1.33, and 1.95 for RTOG-0617, HARVARD-CRT, and HARVARD-DURVA, respectively). Patients with preserved thymic health (TH) before radiotherapy seemed to have a particularly greater risk; in patients with impaired TH, no associations emerged. Dose-dependent declines in TH and lower circulating lymphocyte counts were demonstrated in one-year follow-up imaging.
“The patients who benefit most from immunotherapy may also be the ones who benefit most from protecting the thymus during radiation treatment,” co-senior author Raymond H. Mak, M.D., from Mass General Brigham Cancer Institute, said in a statement. “[These studies] reinforce the broader concept that successful cancer treatment is not only about eliminating the tumor, but also about preserving the patient”s immune system.”
Several authors disclosed ties to the biopharmaceutical industry.
ESMO: Combination Treatment Improves Survival in Muscle-Invasive Bladder Cancer
Broad Genomic Sequencing Improves Survival in First-Line Setting in Advanced NSCLC
Morphea Linked to Higher Risk for Cancer
Guidelines Updated for Short-Course Radiation for Localized Prostate Cancer
Guidelines Updated for Prostate Cancer Screening
Early Survivorship Care Linked to Improved Outcomes in Head, Neck Cancer
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer
Pre-Prostate Biopsy MRI Use Increased From 2017 to 2026